World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 78 17885 16812 224 214 712 27663

Ahmad Awada publications per year

The chart shows the history of publications by Ahmad Awada between 1992 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Ahmad Awada published across 35 years, from 1992 to 2026, averaging 26.7 papers a year. Output peaked at 128 publications in 2023. 28 of the 936 publications appeared in the last two years.

No. of publications
25 50 75 100 125
Bar chart. Horizontal axis: year, 1992 to 2026. Vertical axis: number of publications, 0 to 128. Peak 128 publications in 2023. 1992: 6 publications 1993: 2 publications 1994: 3 publications 1995: 3 publications 1996: 4 publications 1997: 9 publications 1998: 10 publications 1999: 6 publications 2000: 7 publications 2001: 11 publications 2002: 13 publications 2003: 10 publications 2004: 23 publications 2005: 14 publications 2006: 26 publications 2007: 23 publications 2008: 37 publications 2009: 35 publications 2010: 35 publications 2011: 29 publications 2012: 37 publications 2013: 38 publications 2014: 41 publications 2015: 34 publications 2016: 48 publications 2017: 41 publications 2018: 35 publications 2019: 40 publications 2020: 38 publications 2021: 44 publications 2022: 46 publications 2023: 128 publications 2024: 32 publications 2025: 27 publications 2026: 1 publication
1992 2026

936 publications in total across all disciplines

View publications per year as a table
Ahmad Awada: publications per year, 1992 to 2026
Year Publications
1992 6
1993 2
1994 3
1995 3
1996 4
1997 9
1998 10
1999 6
2000 7
2001 11
2002 13
2003 10
2004 23
2005 14
2006 26
2007 23
2008 37
2009 35
2010 35
2011 29
2012 37
2013 38
2014 41
2015 34
2016 48
2017 41
2018 35
2019 40
2020 38
2021 44
2022 46
2023 128
2024 32
2025 27
2026 1
Total 936
Download as CSV

Ahmad Awada publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ahmad Awada sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 701–720 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 712 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307 712
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Ahmad Awada D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ahmad Awada sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 78–79 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891 78
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Ahmad Awada is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in Oncology, Pulmonary and Respiratory Medicine, and Molecular Biology as key subfields.

The main topics addressed in their research include:

  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Brain Metastases and Treatment

Among the frequent publication venues for Awada's work are:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • Clinical Cancer Research

Co-authors with multiple collaborations include:

  • Nuria Kotecki
  • Evandro de Azambuja
  • Martine Piccart
  • Philippe Aftimos
  • Marianne Paesmans

Recent papers featuring Ahmad Awada encompass:

  • Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial (2020, UNC Libraries)
  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial (2020, The Lancet Oncology) [awada is not author]
  • A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer (2020, Clinical Cancer Research) [awada is not author]
  • A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours (2020, British Journal of Cancer) [awada is not author]
  • Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research (2021, Frontiers in Oncology) [awada is not author]

Ahmad Awada's research shows a focus on clinical trials and cancer treatment methodologies, particularly related to breast cancer therapies and brain metastases. The collaborations and publication venues indicate an active engagement with leading oncology research communities.

Best Publications

  • Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

    Jan B. Vermorken;Eva Remenar;Carla Van Herpen;Thierry Gorlia

  • Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

    Dirk Strumberg;Heike Richly;Ralf A. Hilger;Norbert Schleucher

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    José Baselga;Seock Ah Im;Hiroji Iwata;Javier Cortés

  • Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

    Harold J. Burstein;Yan Sun;Luc Y. Dirix;Zefei Jiang

  • Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

    Dirk Strumberg;Jeffrey W. Clark;Ahmad Awada;Malcolm J. Moore

  • Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Peter A. Kaufman;Ahmad Awada;Chris Twelves;Louise Yelle

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

    Tiffany T.A. Traina;Tiffany T.A. Traina;Kathy Miller;Denise Yardley;Janice Eakle

  • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

    A Awada;A Hendlisz;T Gil;S Bartholomeus

  • Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

    Christian Widakowich;Christian Widakowich;Gilberto de Castro;Evandro de Azambuja;Evandro de Azambuja;Phuong Dinh

  • Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

    José Baselga;Patricia Gómez;Richard Greil;Sofia Braga

  • Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

    Sophie Leboulleux;Lars Bastholt;Thomas Michael Krause;Christelle de la Fouchardiere

  • Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

    G Gebhart;L. E Lamberts;Z Wimana;C Garcia

  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    José Trigo;Vivek Subbiah;Benjamin Besse;Benjamin Besse;Victor Moreno

  • Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

    Ahmad Awada;Ramon Colomer;Kenichi Inoue;Igor Bondarenko

  • Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    Javier Cortes;Linda Vahdat;Joanne L. Blum;Chris Twelves

  • Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

    Lillian L. Siu;Ahmad Awada;Chris H. Takimoto;Martine Piccart

  • Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

    F Rothé;J-F Laes;Diether Lambrechts;Dominiek Smeets

  • Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

    Chris C. Twelves;Javier Cortes;Linda L.T. Vahdat;Martin M. Olivo

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Marianne Paesmans
Marianne Paesmans Université Libre de Bruxelles
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Véronique Diéras
Véronique Diéras Institute Curie
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Hans Wildiers
Hans Wildiers KU Leuven
Denis Larsimont
Denis Larsimont Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens up diverse career pathways beyond traditional medical practice. Many students consider related online degrees that offer flexibility and affordability. For those interested in advanced nursing, exploring the cheapest DNP program options can help you achieve a doctoral-level qualification at a lower cost.

If you're passionate about pharmaceuticals, attending a pharmacy school online provides a convenient way to earn a PharmD degree without relocating. Alternatively, careers in health administration and data management are growing. Getting an online health information management degree prepares you for roles in medical records, analysis, and information systems.

Entry-level options are also available for those seeking faster pathways into healthcare. Completing a low cost medical coding and billing online program can help you quickly start working in healthcare administration. Each pathway offers its own set of rewards and challenges, so it's important to choose a degree that matches your career goals.

Best Scientists Citing Ahmad Awada

Trending Scientists

Recently Published Articles